Related references
Note: Only part of the references are listed.CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Brian Leyland-Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
Lei Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
DMET-Analyzer: automatic analysis of Affymetrix DMET Data
Pietro Hiram Guzzi et al.
BMC BIOINFORMATICS (2012)
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
Roberta Ferraldeschi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Pharmacogenomics of third-generation aromatase inhibitors
Abdullah Turkistani et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Pharmacogenetics of aromatase inhibitors
Kristen D. Hadfield et al.
PHARMACOGENOMICS (2012)
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
In Hae Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
Z. Desta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
A polymorphism at the 3′-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
Zaida Garcia-Casado et al.
BMC CANCER (2010)
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
Rob Riemsma et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Liewei Wang et al.
CANCER RESEARCH (2010)
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
PGA: power calculator for case-control genetic association analyses
Idan Menashe et al.
BMC GENETICS (2008)
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
Ramon Colomer et al.
CLINICAL CANCER RESEARCH (2008)
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Mitch Dowsett et al.
CLINICAL CANCER RESEARCH (2008)
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:: The BIG 1-98 trial
Diana Crivellari et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer
B. Moy et al.
ANNALS OF ONCOLOGY (2006)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
Human aromatase: Gene resequencing and functional genomics
CX Ma et al.
CANCER RESEARCH (2005)
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
R Paridaens et al.
ANNALS OF ONCOLOGY (2003)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Polymorphism of the aromatase gene in postmenopausal Italian women: Distribution and correlation with bone mass and fracture risk
L Masi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Share Paper
